The ability of embryonic stem cells to differentiate into different types of cells with different functions is regulated and maintained by a complex series of chemical interactions, which are not well understood. Learning more about this process could prove useful for stem cell-based therapies down the road. New research from a team led by Carnegie’s Yixian Zheng zeroes in on the process by which stem cells maintain their proper undifferentiated state. Their results are published in Cell.
Embryonic stem cells go through a process called self-renewal, wherein they undergo multiple cycles of division while not differentiating into any other type of cells. This process is dependent on three protein networks, which guide both self-renewal and eventual differentiation. But the integration of these three networks has remained a mystery.
Using a combination of genetic, protein-oriented and physiological approaches involving mouse embryonic stem cells, the team – which also included current and former Carnegie scientists Junling Jia, Xiaobin Zheng, Junqi Zhang, Anying Zhang, and Hao Jiang – uncovered a mechanism that integrates all three networks involved in embryonic stem cell self-renewal and provide a critical missing link to understanding this process.
The key is a protein called Utf1. It serves three important roles. First, it balances between activating and deactivating the necessary genes to direct the cell toward differentiation. At the same time, it acts on messenger RNA that is the transcription product of the genes when they’re activated by tagging it for degradation, rather than allowing it to continue to serve its cellular function. Lastly, it blocks a genetic feedback loop that normally inhibits cellular proliferation, allowing it to occur in the rapid nature characteristic of embryonic stem cells.
“We are slowly but surely growing to understand the physiology of embryonic stem cells,” Zheng said. “It is crucial that we continue to carrying out basic research on how these cells function.”
Non-Carnegie co-authors on the paper include Gangquing Hu, Kairong Cui, Chengyu Liu and Keji Zhao of the National Institutes of Health; and John Yates III and Bingwen Lu of the Scripps Research Institute, the latter of whom is now at Pfizer.
This research was supported by NIH, NHLBI intramural research, HHMI, and the Cystic Fibrosis Foundation Therapeutics Inc.